Free Trial
NASDAQ:SNPX

Synaptogenix 5/15/2024 Earnings Report

Synaptogenix logo
$5.83 -0.44 (-7.02%)
As of 09/19/2025

Synaptogenix EPS Results

Actual EPS
-$0.41
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Synaptogenix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Synaptogenix Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Synaptogenix Earnings Headlines

Synaptogenix (NASDAQ:SNPX) Stock Price Down 4.2% - What's Next?
Buffett, Gates and Bezos Dumping Stocks
The world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century.tc pixel
See More Synaptogenix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synaptogenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synaptogenix and other key companies, straight to your email.

About Synaptogenix

Synaptogenix (NASDAQ:SNPX) is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of small‐molecule therapeutics aimed at preserving or restoring synaptic function in neurodegenerative diseases. Its research focuses on addressing the cognitive impairment associated with conditions such as Alzheimer’s disease by targeting pathways critical to neuronal communication and synaptic health.

The company’s lead candidate is in early‐phase clinical studies to assess safety, tolerability and potential efficacy in improving cognitive deficits. Leveraging a proprietary drug discovery platform, Synaptogenix has built a pipeline of novel compounds designed to modulate key synaptic processes and slow disease progression. Research collaborations with academic institutions and neuroscience centers support its preclinical and clinical development efforts.

Based in the United States, Synaptogenix operates laboratories and research facilities focused exclusively on neuroscience drug discovery. The management team brings together professionals with extensive experience in biotechnology and neurodegenerative disease research, guiding the company’s mission to develop innovative treatments for patients suffering from cognitive disorders.

View Synaptogenix Profile

More Earnings Resources from MarketBeat